Comparative Pharmacology
Head-to-head clinical analysis: PSORCON E versus U CORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PSORCON E versus U CORT.
PSORCON E vs U-CORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory, antipruritic, and vasoconstrictive effects.
U-CORT (hydrocortisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and subsequent anti-inflammatory, immunosuppressive, and metabolic effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses cytokine production and immune cell migration.
Topical: Apply a thin film to affected skin areas twice daily. No systemic dosing applicable.
U-CORT (hydrocortisone) 100 mg intravenous bolus, followed by 100 mg intravenous every 8 hours for 48 hours, then taper as clinically indicated.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours for the parent compound; active metabolites may have half-lives up to 12 hours. Clinically, this supports twice-daily dosing.
Terminal half-life approximately 1.6-2.2 hours; clinically used as short-acting topical corticosteroid.
Primarily hepatic metabolism followed by renal excretion of metabolites; less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for <2%.
Primarily hepatic metabolism; inactive metabolites excreted renally (60-70%) and biliary/fecal (20-30%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid